Cardiac Insight

What Cardiac Insight does

Cardiac Insight, Inc. is a privately held medical device company headquartered in Bellevue, Washington, founded in 2013 by Dr. David Hadley and Dr. Victor Froelicher. The company develops and sells two core ECG diagnostic products: Cardea SOLO, a 23-gram water-resistant single-use wearable ambulatory sensor that continuously records up to one million heartbeats over seven days and pairs with a Windows-based analysis software that produces draft diagnostic reports in under five minutes; and Cardea 20/20, a handheld 12-lead ECG system that embeds the International Consensus Criteria for athlete screening and reports an industry-low ~2% false positive rate (vs. a ~30% industry norm). Cardiac Insight serves three distinct customer segments — healthcare providers and cardiology practices (primary), sports organizations and athletic programs (primary, including MLB's LA Dodgers and MLS's LA Galaxy), and academic/pharmaceutical researchers — through a direct sales motion supported by phone, a Sales Hub portal, and event-driven community partnerships.

Cardiac Insight generates revenue primarily through capital hardware sales of the Cardea 20/20 device and recurring unit sales of single-use Cardea SOLO sensors, supplemented by software licensing for the SOLO analysis platform. Providers retain full Category I CPT reimbursement for long-term ECG monitoring because the in-office software eliminates third-party IDTF data transfer. The company is a subsidiary of DreamTech, a KOSPI-listed Korean electronic components manufacturer that acquired Cardiac Insight in 2022 and whose CEO Min Kim also serves as Cardiac Insight's CEO. Following the acquisition, the company has expanded its leadership bench (COO, CSO, CMO, President/CGO) and is scaling commercial operations, supported by community screening partnerships with Who We Play For, Vegas Has a Heart, and Parent Heart Watch, and a research sales channel offering flexible, contract-free ordering for academic and pharmaceutical users.

Name

Cardiac Insight

Legal name

Cardiac Insight, Inc.

Website

https://cardiacinsightinc.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Cardiac Insight is a Bellevue, WA-based privately held medical device company that develops and sells the Cardea SOLO 7-day wearable ECG sensor and the Cardea 20/20 12-lead athlete-screening ECG system to healthcare providers, sports organizations, and academic researchers, and is a subsidiary of Korea's DreamTech.

Ownership category

akta.pro rank

Headquarters

HQ city

Bellevue

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. ECG Device Sales: Cardiac Insight generates revenue through the sale of its ECG monitoring devices including the Cardea SOLO wearable sensor and Cardea 20/20 12-lead ECG system. These are capital medical device purchases by healthcare providers and sports organizations.
2. Software Licensing: The company sells licenses for its proprietary Cardea SOLO analysis software which installs on Windows PCs. Software generates diagnostic reports and provides clinical tools for ECG interpretation.
3. Healthcare Reimbursement: Providers using Cardea SOLO receive reimbursement through Category I CPT codes for long-term ECG monitoring. The company supports global billing allowing providers to retain full reimbursement without sharing with IDTF centers. Reimbursement rates have increased, making it cost-effective for providers.
4. Research & Academic Sales: Cardea SOLO is offered to academic institutions, pharmaceutical companies, and industry researchers for ECG data collection in clinical studies, with flexible ordering without long-term contracts.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Cardiac Insight designs, manufactures, and sells wearable and handheld ECG diagnostic devices and proprietary analysis software for cardiac monitoring and screening. Its flagship products are the Cardea SOLO 7-day wearable ambulatory ECG sensor with companion Windows analysis software, and the Cardea 20/20 handheld 12-lead ECG system purpose-built for athlete cardiac screening. The company sells primarily to healthcare providers, sports organizations, and academic research institutions.

Product overview

Cardiac Insight offers two core ECG diagnostic products: Cardea SOLO and Cardea 20/20. Cardea SOLO is a 7-day wearable ambulatory ECG monitoring system for detecting arrhythmias in general patients, comprising a disposable sensor, smart cable, and proprietary analysis software. Cardea 20/20 is a handheld 12-lead ECG device specifically designed for athlete cardiac screening using International Consensus Criteria. Both products feature proprietary automated analysis algorithms, though they serve different clinical use cases—continuous long-term monitoring for Cardea SOLO versus point-of-care 12-lead screening for Cardea 20/20.

Differentiator

Problem solved

Functional benefit

Brands

• Cardea SOLO: A 7-day wearable ambulatory ECG sensor with software-assisted ECG analysis for detecting cardiac arrhythmias.
• Cardea 20/20

Products and services

• Cardea SOLO ECG System A wearable ambulatory ECG monitoring system consisting of a lightweight 23g water-resistant sensor worn for up to 7 days, a smart USB cable, and proprietary analysis software that generates diagnostic reports in under 5 minutes with over 96% positive predictive value for arrhythmia detection. Designed for healthcare providers to conduct continuous cardiac monitoring for arrhythmia detection, atrial fibrillation diagnosis, and cardiac event monitoring in patient populations.
• Cardea 20/20 ECG System A handheld 12-lead ECG diagnostic system designed specifically for athlete cardiac screening, featuring automated interpretation algorithms with the lowest false positive rate in the industry (~2%) using International Consensus Criteria, 16-second recording duration, and USB connectivity to Windows PCs. Built for sports medicine physicians, athletic programs, and sports organizations conducting pre-participation athlete screening and sudden cardiac arrest prevention.

Quantifiable outcome

• False positive rate reduced to ~2% compared to industry norm of 30%
• +5 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature5 records

Partnerships

Six partnerships are on record, tiered major, significant and minor.

• Parent Heart WatchmajorStrategic or Co-development Partner · 3 April 2026Cardiac Insight supported Parent Heart Watch's second annual National Youth Heart Screening Day, providing free ECG screenings to over 2,400 children and young adults across 14 states. The event identified 53 youth at risk for sudden cardiac arrest and included emergency response training.
• Who We Play FormajorStrategic or Co-development PartnerWho We Play For is a nonprofit organization focused on preventing sudden cardiac arrest in young athletes. Cardiac Insight serves as the official ECG provider for Who We Play For's screening events, powering free heart screenings across schools and communities.
• Vegas Has a HeartsignificantStrategic or Co-development PartnerVegas Has a Heart is a nonprofit collaborating with Cardiac Insight to screen student athletes for cardiac issues. The organization has partnered with notable figures including Shaq (Shaquille O'Neal) and Gatorade Player of the Year Xavion Stanton to raise awareness for sudden cardiac arrest prevention.
• LA DodgerssignificantGTM or Marketing PartnerMLB's Los Angeles Dodgers partnered with Cardiac Insight for athlete heart screening initiatives. Players including Joe Kelly, Tony Gonsolin, and Matt McLain have supported the #CheckYourHeart national movement to raise awareness for youth heart screenings.
• LA GalaxyminorGTM or Marketing PartnerMLS team LA Galaxy partnered with Cardiac Insight for athlete cardiac screening using Cardea 20/20 ECG technology.
• Liquid Packaging SolutionsminorGTM or Marketing PartnerLiquid Packaging Solutions supported the National Youth Heart Screening Day event alongside Cardiac Insight and Parent Heart Watch.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• iRhythm Technologies: iRhythm's Zio XT and Zio AT are the leading ambulatory ECG patch monitors in the US market and the primary direct competitor to Cardea SOLO. Both companies serve healthcare providers needing 7-14 day continuous cardiac monitoring with automated arrhythmia detection.
• Bardy Diagnostics (BardyDX): BardyDX's CAM Patch is a direct competitor in ambulatory ECG monitoring, with a similar single-use patch design and up to 14-day wear period. BardyDX was acquired by Hillrom, providing distribution scale through Baxter's clinical channels.
• Preventice Solutions: Preventice developed the BodyGuardian MINI family of remote cardiac monitors, a direct competitor to Cardea SOLO in ambulatory ECG monitoring. Now part of Boston Scientific, it competes across diagnostic, monitoring, and connected health workflows.

Broad incumbents

• Philips: Philips' ePatch ambulatory ECG monitor directly competes with Cardea SOLO in the extended cardiac monitoring space. As a global medtech incumbent, Philips has broader product portfolio, larger distribution, and deeper hospital relationships than Cardiac Insight.
• Boston Scientific: Boston Scientific's BodyGuardian MINI (acquired via Preventice Solutions) is a direct ambulatory ECG competitor to Cardea SOLO. Boston Scientific brings significantly larger R&D, sales, and regulatory resources to the cardiac monitoring category.
• GE HealthCare: GE HealthCare offers a broad portfolio of cardiac diagnostic and monitoring solutions including ECG systems, patient monitors, and ambulatory devices. While not a direct competitor in the ambulatory patch niche, it competes for the same cardiology budgets and hospital relationships.
• Medtronic: Medtronic has a broad cardiac diagnostics and monitoring portfolio including insertable cardiac monitors (Reveal LINQ) and remote monitoring infrastructure that competes with Cardiac Insight in arrhythmia detection, though it primarily addresses the implantable rather than wearable ambulatory segment.

Emerging players

• AliveCor: AliveCor's KardiaMobile devices offer single-lead ECG recording for both consumer and clinical use, overlapping with Cardiac Insight's arrhythmia detection focus but emphasizing shorter-duration, consumer-friendly form factors versus 7-day ambulatory wear.
• Eko Health: Eko Health combines digital stethoscopes with AI-powered ECG and cardiac disease detection, overlapping with Cardiac Insight's diagnostic screening use cases — particularly in primary care and athlete screening workflows. Emerging player with growing clinical adoption.

Others

• Apple: Apple Watch ECG functionality represents an indirect consumer-grade competitor for cardiac rhythm monitoring and arrhythmia detection. While not a clinical-grade substitute, Apple Watch ECG normalizes self-monitoring behavior and could either expand the market or commoditize low-acuity arrhythmia screening.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/cardiacinsight
• LinkedInlinkedin.com/company/5861346
• Instagraminstagram.com/cardiacinsight
• Xx.com/CardiacInsight

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds12 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cardiac Insight